Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
11 Dezember 2008 - 11:40PM
PR Newswire (US)
NEW BRUNSWICK, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Johnson
& Johnson (NYSE:JNJ) today announced that the Israeli General
Director of the Antitrust Authority has approved Johnson &
Johnson's proposed acquisition of Omrix Biopharmaceuticals, Inc.
(NASDAQ:OMRI), under the Restrictive Trade Practices Law 5748-1988
of Israel. Johnson & Johnson announced its intention to acquire
Omrix on November 24, 2008. It commenced, through a new
wholly-owned subsidiary, Binder Merger Sub, Inc., a cash tender
offer on November 25, 2008, to purchase all outstanding shares of
common stock of Omrix for $25.00 per share, less any required
withholding taxes. The approval, which was dated December 10, 2008,
satisfies one of the conditions to the tender offer, which is set
to expire at 12:00 midnight on December 23, 2008. The tender offer
is also conditioned on the tender of a majority of the outstanding
shares of Omrix's common stock on a fully diluted basis, the
approval by the Investment Center of Israel of the proposed
acquisition and the satisfaction of other customary closing
conditions. About Johnson & Johnson Caring for the world, one
person at a time ... inspires and unites the people of Johnson
& Johnson. We embrace research and science - bringing
innovative ideas, products and services to advance the health and
well-being of people. Our 119,400 employees at more than 250
Johnson & Johnson companies work with partners in health care
to touch the lives of over a billion people every day, throughout
the world. Additional Information This press release is neither an
offer to purchase nor a solicitation of an offer to sell shares of
Omrix Biopharmaceuticals, Inc. Johnson & Johnson and Binder
Merger Sub, Inc. have filed a tender offer statement with the
Securities and Exchange Commission ("SEC"), and have mailed an
offer to purchase, forms of letter of transmittal and related
documents to Omrix stockholders. Omrix has filed with the SEC, and
has mailed to Omrix stockholders, a solicitation/recommendation
statement on Schedule 14D-9. These documents contain important
information about the tender offer and stockholders of Omrix are
urged to read them carefully. These documents are available at no
charge at the SEC's website at http://www.sec.gov/. The tender
offer statement and the related materials may be obtained for free
by directing a request by mail to Georgeson Inc., 199 Water Street,
New York, New York 10038 or by calling toll-free (888) 679-2897. In
addition, a copy of the offer to purchase, letter of transmittal
and certain other related tender offer documents may be obtained
free of charge by directing a request to Johnson & Johnson at
http://www.jnj.com/, or Johnson & Johnson, One Johnson &
Johnson Plaza, New Brunswick, NJ 08933, Attn: Corporate Secretary's
Office. DATASOURCE: Johnson & Johnson CONTACT: Jeffrey J.
Leebaw, +1-732-524-3350, or +1-732-642-6608 (M); or Bill Price.
+1-732-524-6623, or +1-732-668-3735 (M); or Investor Contacts:
Louise Mehrotra, +1-732-524-6491; or Stan Panasewicz,
+1-732-524-2524 Web Site: http://www.jnj.com/
Copyright
Omrix Biopharmaceuticals (MM) (NASDAQ:OMRI)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Omrix Biopharmaceuticals (MM) (NASDAQ:OMRI)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Omrix Biopharmaceuticals (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Omrix Biopharmaceuticals (MM) News-Artikel